The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Plasma-derived Factor VIII-Global Market Insights and Sales Trends 2025
Synopsis
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A.
The global Plasma-derived Factor VIII market size is expected to reach US$ 12950 million by 2029, growing at a CAGR of 5.7% from 2023 to 2029. The market is mainly driven by the significant applications of Plasma-derived Factor VIII in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Plasma-derived Factor VIII market. 200IU, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 250IU segment is estimated at % CAGR for the next seven-year period.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of hemophilia A and the rising awareness about the importance of early diagnosis and treatment have led to a growing demand for Factor VIII products. The availability of plasma-derived Factor VIII provides an effective treatment option for patients who require clotting factor replacement therapy. Secondly, advancements in manufacturing techniques and purification processes have improved the safety and efficacy of plasma-derived Factor VIII products. Stringent regulatory standards and guidelines for plasma collection and fractionation have instilled confidence among healthcare providers and patients regarding the safety of these products.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Plasma-derived Factor VIII, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Plasma-derived Factor VIII market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Plasma-derived Factor VIII market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Plasma-derived Factor VIII sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Plasma-derived Factor VIII covered in this report include Takeda, Octapharma, CSL, Grifols, Greencross, Kedrion, BPL, Hualan Bio and RAAS, etc.
The global Plasma-derived Factor VIII market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Global Plasma-derived Factor VIII market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Plasma-derived Factor VIII market, Segment by Type:
200IU
250IU
Global Plasma-derived Factor VIII market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Plasma-derived Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
RECOMBINATE is recombinant Factor VIII, a clotting factor that is deficient in people with hemophilia A.
The global Plasma-derived Factor VIII market size is expected to reach US$ 12950 million by 2029, growing at a CAGR of 5.7% from 2023 to 2029. The market is mainly driven by the significant applications of Plasma-derived Factor VIII in various end use industries. The expanding demands from the Hospital and Pharmacy, are propelling Plasma-derived Factor VIII market. 200IU, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 250IU segment is estimated at % CAGR for the next seven-year period.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of hemophilia A and the rising awareness about the importance of early diagnosis and treatment have led to a growing demand for Factor VIII products. The availability of plasma-derived Factor VIII provides an effective treatment option for patients who require clotting factor replacement therapy. Secondly, advancements in manufacturing techniques and purification processes have improved the safety and efficacy of plasma-derived Factor VIII products. Stringent regulatory standards and guidelines for plasma collection and fractionation have instilled confidence among healthcare providers and patients regarding the safety of these products.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Plasma-derived Factor VIII, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Plasma-derived Factor VIII market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Plasma-derived Factor VIII market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Plasma-derived Factor VIII sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Plasma-derived Factor VIII covered in this report include Takeda, Octapharma, CSL, Grifols, Greencross, Kedrion, BPL, Hualan Bio and RAAS, etc.
The global Plasma-derived Factor VIII market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Takeda
Octapharma
CSL
Grifols
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Global Plasma-derived Factor VIII market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Plasma-derived Factor VIII market, Segment by Type:
200IU
250IU
Global Plasma-derived Factor VIII market, by Application
Hospital
Pharmacy
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Plasma-derived Factor VIII manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Plasma-derived Factor VIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Plasma-derived Factor VIII Market Overview
1.1 Plasma-derived Factor VIII Product Overview
1.2 Plasma-derived Factor VIII Market Segment by Type
1.2.1 200IU
1.2.2 250IU
1.3 Global Plasma-derived Factor VIII Market Size by Type
1.3.1 Global Plasma-derived Factor VIII Market Size Overview by Type (2018-2029)
1.3.2 Global Plasma-derived Factor VIII Historic Market Size Review by Type (2018-2023)
1.3.3 Global Plasma-derived Factor VIII Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Plasma-derived Factor VIII Sales Breakdown by Type (2018-2023)
1.4.2 Europe Plasma-derived Factor VIII Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Plasma-derived Factor VIII Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Plasma-derived Factor VIII Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Plasma-derived Factor VIII Sales Breakdown by Type (2018-2023)
2 Global Plasma-derived Factor VIII Market Competition by Company
2.1 Global Top Players by Plasma-derived Factor VIII Sales (2018-2023)
2.2 Global Top Players by Plasma-derived Factor VIII Revenue (2018-2023)
2.3 Global Top Players by Plasma-derived Factor VIII Price (2018-2023)
2.4 Global Top Manufacturers Plasma-derived Factor VIII Manufacturing Base Distribution, Sales Area, Product Type
2.5 Plasma-derived Factor VIII Market Competitive Situation and Trends
2.5.1 Plasma-derived Factor VIII Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Plasma-derived Factor VIII Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Plasma-derived Factor VIII as of 2022)
2.7 Date of Key Manufacturers Enter into Plasma-derived Factor VIII Market
2.8 Key Manufacturers Plasma-derived Factor VIII Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Plasma-derived Factor VIII Status and Outlook by Region
3.1 Global Plasma-derived Factor VIII Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Plasma-derived Factor VIII Historic Market Size by Region
3.2.1 Global Plasma-derived Factor VIII Sales in Volume by Region (2018-2023)
3.2.2 Global Plasma-derived Factor VIII Sales in Value by Region (2018-2023)
3.2.3 Global Plasma-derived Factor VIII Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Plasma-derived Factor VIII Forecasted Market Size by Region
3.3.1 Global Plasma-derived Factor VIII Sales in Volume by Region (2024-2029)
3.3.2 Global Plasma-derived Factor VIII Sales in Value by Region (2024-2029)
3.3.3 Global Plasma-derived Factor VIII Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Plasma-derived Factor VIII by Application
4.1 Plasma-derived Factor VIII Market Segment by Application
4.1.1 Hospital
4.1.2 Pharmacy
4.2 Global Plasma-derived Factor VIII Market Size by Application
4.2.1 Global Plasma-derived Factor VIII Market Size Overview by Application (2018-2029)
4.2.2 Global Plasma-derived Factor VIII Historic Market Size Review by Application (2018-2023)
4.2.3 Global Plasma-derived Factor VIII Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Plasma-derived Factor VIII Sales Breakdown by Application (2018-2023)
4.3.2 Europe Plasma-derived Factor VIII Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Plasma-derived Factor VIII Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Plasma-derived Factor VIII Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Plasma-derived Factor VIII Sales Breakdown by Application (2018-2023)
5 North America Plasma-derived Factor VIII by Country
5.1 North America Plasma-derived Factor VIII Historic Market Size by Country
5.1.1 North America Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Plasma-derived Factor VIII Sales in Volume by Country (2018-2023)
5.1.3 North America Plasma-derived Factor VIII Sales in Value by Country (2018-2023)
5.2 North America Plasma-derived Factor VIII Forecasted Market Size by Country
5.2.1 North America Plasma-derived Factor VIII Sales in Volume by Country (2024-2029)
5.2.2 North America Plasma-derived Factor VIII Sales in Value by Country (2024-2029)
6 Europe Plasma-derived Factor VIII by Country
6.1 Europe Plasma-derived Factor VIII Historic Market Size by Country
6.1.1 Europe Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Plasma-derived Factor VIII Sales in Volume by Country (2018-2023)
6.1.3 Europe Plasma-derived Factor VIII Sales in Value by Country (2018-2023)
6.2 Europe Plasma-derived Factor VIII Forecasted Market Size by Country
6.2.1 Europe Plasma-derived Factor VIII Sales in Volume by Country (2024-2029)
6.2.2 Europe Plasma-derived Factor VIII Sales in Value by Country (2024-2029)
7 Asia-Pacific Plasma-derived Factor VIII by Region
7.1 Asia-Pacific Plasma-derived Factor VIII Historic Market Size by Region
7.1.1 Asia-Pacific Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Plasma-derived Factor VIII Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Plasma-derived Factor VIII Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Plasma-derived Factor VIII Forecasted Market Size by Region
7.2.1 Asia-Pacific Plasma-derived Factor VIII Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Plasma-derived Factor VIII Sales in Value by Region (2024-2029)
8 Latin America Plasma-derived Factor VIII by Country
8.1 Latin America Plasma-derived Factor VIII Historic Market Size by Country
8.1.1 Latin America Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Plasma-derived Factor VIII Sales in Volume by Country (2018-2023)
8.1.3 Latin America Plasma-derived Factor VIII Sales in Value by Country (2018-2023)
8.2 Latin America Plasma-derived Factor VIII Forecasted Market Size by Country
8.2.1 Latin America Plasma-derived Factor VIII Sales in Volume by Country (2024-2029)
8.2.2 Latin America Plasma-derived Factor VIII Sales in Value by Country (2024-2029)
9 Middle East and Africa Plasma-derived Factor VIII by Country
9.1 Middle East and Africa Plasma-derived Factor VIII Historic Market Size by Country
9.1.1 Middle East and Africa Plasma-derived Factor VIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Plasma-derived Factor VIII Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Plasma-derived Factor VIII Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Plasma-derived Factor VIII Forecasted Market Size by Country
9.2.1 Middle East and Africa Plasma-derived Factor VIII Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Plasma-derived Factor VIII Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Takeda
10.1.1 Takeda Company Information
10.1.2 Takeda Introduction and Business Overview
10.1.3 Takeda Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Takeda Plasma-derived Factor VIII Products Offered
10.1.5 Takeda Recent Development
10.2 Octapharma
10.2.1 Octapharma Company Information
10.2.2 Octapharma Introduction and Business Overview
10.2.3 Octapharma Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Octapharma Plasma-derived Factor VIII Products Offered
10.2.5 Octapharma Recent Development
10.3 CSL
10.3.1 CSL Company Information
10.3.2 CSL Introduction and Business Overview
10.3.3 CSL Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.3.4 CSL Plasma-derived Factor VIII Products Offered
10.3.5 CSL Recent Development
10.4 Grifols
10.4.1 Grifols Company Information
10.4.2 Grifols Introduction and Business Overview
10.4.3 Grifols Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Grifols Plasma-derived Factor VIII Products Offered
10.4.5 Grifols Recent Development
10.5 Greencross
10.5.1 Greencross Company Information
10.5.2 Greencross Introduction and Business Overview
10.5.3 Greencross Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Greencross Plasma-derived Factor VIII Products Offered
10.5.5 Greencross Recent Development
10.6 Kedrion
10.6.1 Kedrion Company Information
10.6.2 Kedrion Introduction and Business Overview
10.6.3 Kedrion Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Kedrion Plasma-derived Factor VIII Products Offered
10.6.5 Kedrion Recent Development
10.7 BPL
10.7.1 BPL Company Information
10.7.2 BPL Introduction and Business Overview
10.7.3 BPL Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.7.4 BPL Plasma-derived Factor VIII Products Offered
10.7.5 BPL Recent Development
10.8 Hualan Bio
10.8.1 Hualan Bio Company Information
10.8.2 Hualan Bio Introduction and Business Overview
10.8.3 Hualan Bio Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Hualan Bio Plasma-derived Factor VIII Products Offered
10.8.5 Hualan Bio Recent Development
10.9 RAAS
10.9.1 RAAS Company Information
10.9.2 RAAS Introduction and Business Overview
10.9.3 RAAS Plasma-derived Factor VIII Sales, Revenue and Gross Margin (2018-2023)
10.9.4 RAAS Plasma-derived Factor VIII Products Offered
10.9.5 RAAS Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Plasma-derived Factor VIII Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Plasma-derived Factor VIII Industrial Chain Analysis
11.4 Plasma-derived Factor VIII Market Dynamics
11.4.1 Plasma-derived Factor VIII Industry Trends
11.4.2 Plasma-derived Factor VIII Market Drivers
11.4.3 Plasma-derived Factor VIII Market Challenges
11.4.4 Plasma-derived Factor VIII Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Plasma-derived Factor VIII Distributors
12.3 Plasma-derived Factor VIII Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
